HomeCompareDMPHF vs EPRT

DMPHF vs EPRT: Dividend Comparison 2026

DMPHF yields 2.17% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $36.6K in total portfolio value
10 years
DMPHF
DMPHF
● Live price
2.17%
Share price
$48.60
Annual div
$1.05
5Y div CAGR
14%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.8K
Annual income
$1,051.08
Full DMPHF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — DMPHF vs EPRT

📍 EPRT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDMPHFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DMPHF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DMPHF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DMPHF
Annual income on $10K today (after 15% tax)
$184.42/yr
After 10yr DRIP, annual income (after tax)
$893.42/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $10,021.20/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DMPHF + EPRT for your $10,000?

DMPHF: 50%EPRT: 50%
100% EPRT50/50100% DMPHF
Portfolio after 10yr
$45.1K
Annual income
$6,945.90/yr
Blended yield
15.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

DMPHF
No analyst data
Altman Z
2.2
Piotroski
7/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DMPHF buys
0
EPRT buys
0
No recent congressional trades found for DMPHF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDMPHFEPRT
Forward yield2.17%3.92%
Annual dividend / share$1.05$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR14%29%
Portfolio after 10y$26.8K$63.4K
Annual income after 10y$1,051.08$12,840.73
Total dividends collected$5.6K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: DMPHF vs EPRT ($10,000, DRIP)

YearDMPHF PortfolioDMPHF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$10,947$247.34$11,205$505.18$258.00EPRT
2$12,002$288.49$12,672$682.46$670.00EPRT
3$13,179$336.98$14,490$930.48$1.3KEPRT
4$14,496$394.23$16,786$1,282.69$2.3KEPRT
5$15,973$461.99$19,753$1,791.56$3.8KEPRT
6$17,633$542.36$23,677$2,541.64$6.0KEPRT
7$19,505$637.91$29,008$3,672.99$9.5KEPRT
8$21,623$751.80$36,463$5,425.08$14.8KEPRT
9$24,024$887.92$47,238$8,221.57$23.2KEPRT
10$26,757$1,051.08$63,385$12,840.73$36.6KEPRT

DMPHF vs EPRT: Complete Analysis 2026

DMPHFStock

Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.

Full DMPHF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this DMPHF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DMPHF vs SCHDDMPHF vs JEPIDMPHF vs ODMPHF vs KODMPHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.